Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib as Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma With EGFR Mutation
NCT02283424Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2014
- Primary completion
- Oct 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of icotinib in lung adenocarcinoma (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Recurrence-free Survival at 6 months. Status: unknown.
02
Drugs
icotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02283424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283424.